Inflammation as a keystone of bone marrow stroma alterations in primary myelofibrosis

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Desterke, Christophe ^a   Martinaud, Christophe ^a,b   Ruzehaji, Nadira ^a   Le Bousse Kerdilès, Marie Caroline ^a,c,d  

^a HÔPITAL PAUL BROUSSE   (France)

^b PERCY MILITARY HOSPITAL   (France)

^c French Intergroup on Myeloproliferative Neoplasms ^*  (France)

^d GDR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

BONE MARROW STROMA CELL; CHRONIC INFLAMMATION; HEMATOPOIETIC CELL; HUMAN; INFLAMMATION; MESENCHYMAL STROMA CELL; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STROMA; BONE MARROW; COMPLICATION; DATA MINING; DNA METHYLATION; HEMATOPOIETIC STEM CELL; PHYSIOLOGY; PRIMARY MYELOFIBROSIS; STROMA CELL;

BONE MARROW; DATA MINING; DNA METHYLATION; HEMATOPOIETIC STEM CELLS; HUMANS; INFLAMMATION; PRIMARY MYELOFIBROSIS; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84948404222     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/415024     Document Type: Review

References (151)

1. G. C. Gurtner, S. Werner, Y. Barrandon, and M. T. Longaker, "Wound repair and regeneration," Nature, vol. 453, no. 7193, pp. 314-321, 2008.
2. P. J. Campbell and A. R. Green, "The myeloproliferative disorders," The New England Journal of Medicine, vol. 355, no. 23, pp. 2452-2466, 2006.
3. Ö. H. Yilmaz, R. Valdez, B. K. Teisen et al., "Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells," Nature, vol. 441, no. 7092, pp. 475-482, 2006.
4. M. H. G. P. Raaijmakers, S. Mukherjee, S. Guo et al., "Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia," Nature, vol. 464, no. 7290, pp. 852-857, 2010.
5. A. Kode, J. S. Manavalan, I. Mosialou et al., "Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts," Nature, vol. 506, no. 7487, pp. 240-244, 2014.
6. M.-C. Le Bousse-Kerdilès, "Primary myelofbrosis and the 'bad seeds in bad soil' concept," Fibrogenesis & Tissue Repair, vol. 5, no. 1, article S20, 2012.
7. B. S. Wilkins, D. Radia, C. Woodley, S. El Farhi, C. Keohane, and C. N. Harrison, "Resolution of bone marrow fbrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib," Haematologica, vol. 98, no. 12, pp. 1872-1876, 2013.
8. A. Pardanani, C. Finke, R. A. Abdelrahman, T. L. Lasho, and A. Teferi, "Associations and prognostic interactions between circulating levels of hepcidin, ferritin and infammatory cytokines in primary myelofbrosis," American Journal of Hematology, vol. 88, no. 4, pp. 312-316, 2013.
9. A. Heine, P. Brossart, and D. Wolf, "Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?" Blood, vol. 122, no. 23, pp. 3843-3844, 2013.
10. M. Massa, V. Rosti, R. Campanelli, G. Fois, and G. Barosi, "Rapid and long-lasting decrease of T-regulatory cells in patients with myelofbrosis treated with ruxolitinib," Leukemia, vol. 28, no. 2, pp. 449-451, 2014.
11. A. B. Duenas-Perez and A. J. Mead, "Clinical potential of pacri-tinib in the treatment of myelofbrosis," Terapeutic Advances in Hematology, vol. 6, no. 4, pp. 186-201, 2015.
12. M. C. Martyre, N. Romquin, M. C. Le Bousse-Kerdiles, S. Chevillard, B. Benyahia, and B. Dupriez, "Transforming growth factor-β and megakaryocytes in the pathogenesis of idiopathic myelofbrosis," British Journal of Haematology, vol. 88, no. 1, pp. 9-16, 1994.
13. J. P. Annes, Y. Chen, J. S. Munger, and D. B. Rifin, "Integrin αVβ6-mediated activation of latent TGF-β requires the latent TGF-β binding protein-1," Journal of Cell Biology, vol. 165, no. 5, pp. 723-734, 2004.
14. A. Teferi, "Primary myelofbrosis: 2013 update on diagnosis, risk-stratifcation, and management," American Journal of Hematology, vol. 88, no. 2, pp. 141-150, 2013.
15. J.-J. Lataillade, O. Pierre-Louis, H. C. Hasselbalch et al., "Does primary myelofbrosis involve a defective stem cell niche? From concept to evidence," Blood, vol. 112, no. 8, pp. 3026-3035, 2008.
16. C. Martinaud, C. Desterke, J. Konopacki et al., "Osteogenic potential of mesenchymal stromal cells contributes to primary myelofbrosis," Cancer Research, 2015.
17. + stem cells," International Journal of Cancer, vol. 92, no. 4, pp. 484-488, 2001.
18. D. Brouty-Boyér, C. Doucet, D. Clay, M.-C. Le Bousse-Kerdiles, T. J. Lampidis, and B. Azzarone, "Phenotypic diversity in human fbroblasts from myelometaplasic and non-myelometaplasic hematopoietic tissues," International Journal of Cancer, vol. 76, no. 5, pp. 767-773, 1998.
19. A. Teferi, "The forgotten myeloproliferative disorder: myeloid metaplasia," Oncologist, vol. 8, no. 3, pp. 225-231, 2003.
20. J. W. Vardiman, J. Tiele, D. A. Arber et al., "The 2008 revision of the World Health Organization (WHO) classifcation of myeloid neoplasms and acute leukemia: rationale and important changes," Blood, vol. 114, no. 5, pp. 937-951, 2009.
21. F. Cervantes, B. Dupriez, A. Pereira et al., "New prognostic scoring system for primary myelofbrosis based on a study of the International Working Group for myelofbrosis research and treatment," Blood, vol. 113, no. 13, pp. 2895-2901, 2009.
22. C. A. Ortmann, D. G. Kent, J. Nangalia et al., "Efect of mutation order on myeloproliferative neoplasms," The New England Journal of Medicine, vol. 372, no. 7, pp. 601-612, 2015.
23. P. Lundberg, A. Karow, R. Nienhold et al., "Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms," Blood, vol. 123, no. 14, pp. 2220-2228, 2014.
24. I. Triviai, T. Stubig, B. Niebuhr et al., "CD133 marks a stem cell population that drives human primary myelofbrosis," Haematologica, vol. 100, no. 6, pp. 768-779, 2015.
25. C. James, V. Ugo, J.-P. Le Coúedic et al., "A unique clonal JAK2 mutation leading to constitutive signalling causes poly-cythaemia vera," Nature, vol. 434, no. 7037, pp. 1144-1148, 2005.
26. A. D. Pardanani, R. L. Levine, T. Lasho et al., "MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients," Blood, vol. 108, no. 10, pp. 3472-3476, 2006.
27. R. L. Levine, M. Wadleigh, J. Cools et al., "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofbrosis," Cancer Cell, vol. 7, no. 4, pp. 387-397, 2005.
28. J. Nangalia, C. E. Massie, E. J. Baxter et al., "Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2," The New England Journal of Medicine, vol. 369, no. 25, pp. 2391-2405, 2013.
29. A. Teferi, T. L. Lasho, C. M. Finke et al., "CALR vs JAK2 vs MPL-mutated or triple-negative myelofbrosis: clinical, cytoge-netic and molecular comparisons," Leukemia, 2014.
30. T. Klampf, H. Gisslinger, A. S. Harutyunyan et al., "Somatic mutations of calreticulin in myeloproliferative neoplasms," The New England Journal of Medicine, vol. 369, no. 25, pp. 2379-2390, 2013.
31. C. Cleyrat, A. Darehshouri, M. P. Steinkamp et al., "Mpl trafcs to the cell surface through conventional and unconventional routes," Trafc , vol. 15, no. 9, pp. 961-982, 2014.
32. Y. Jiang, S. Dey, and H. Matsunami, "Calreticulin: roles in cell-surface protein expression," Membranes, vol. 4, no. 3, pp. 630-641, 2014.
33. M. Brecqueville, J. Rey, R. Devillier et al., "Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofbrosis at chronic or acute phase," Haematologica, vol. 99, no. 1, pp. 37-45, 2014.
34. N. Fourouclas, J. Li, D. C. Gilby et al., "Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloprolif-erative disorders," Haematologica, vol. 93, no. 11, pp. 1635-1644, 2008.
35. F. Stegelmann, L. Bullinger, M. Griesshammer et al., "High-resolution single-nucleotide polymorphism array-profling in myeloproliferative neoplasms identifes novel genomic aberrations," Haematologica, vol. 95, no. 4, pp. 666-669, 2010.
36. E. Tenedini, I. Bernardis, V. Artusi et al., "Targeted cancer exome sequencing reveals recurrent mutations in myeloprolif-erative neoplasms," Leukemia, vol. 28, no. 5, pp. 1052-1059, 2014.
37. J.-S. Ha, D.-S. Jeon, J.-R. Kim, N.-H. Ryoo, and J.-S. Suh, "Analysis of the ten-eleven translocation 2 (TET2) gene mutation in myeloproliferative neoplasms," Annals of Clinical and Laboratory Science, vol. 44, no. 2, pp. 173-179, 2014.
38. M. Brecqueville, J. Rey, F. Bertucci et al., "Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms," Genes Chromosomes and Cancer, vol. 51, no. 8, pp. 743-755, 2012.
39. M. Brecqueville, J. Adélaïde, F. Bertucci et al., "Alterations of polycomb gene BMI1 in human myeloproliferative neoplasms," Cell Cycle, vol. 11, no. 16, pp. 3141-3142, 2012.
40. R. Schofeld, "The relationship between the spleen colony-forming cell and the haemopoietic stem cell," Blood Cells, vol. 4, no. 1-2, pp. 7-25, 1978.
41. S. J. Morrison and D. T. Scadden, "The bone marrow niche for haematopoietic stem cells," Nature, vol. 505, no. 7483, pp. 327-334, 2014.
42. L. Ding and S. J. Morrison, "Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches," Nature, vol. 495, no. 7440, pp. 231-235, 2013.
43. J. Zhang, C. Niu, L. Ye et al., "Identifcation of the haematopoietic stem cell niche and control of the niche size," Nature, vol. 425, no. 6960, pp. 836-841, 2003.
44. F. Arai, A. Hirao, M. Ohmura et al., "Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche," Cell, vol. 118, no. 2, pp. 149-161, 2004.
45. T. Sugiyama, H. Kohara, M. Noda, and T. Nagasawa, "Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches," Immunity, vol. 25, no. 6, pp. 977-988, 2006.
46. D. A. Sipkins, X. Wei, J. W. Wu et al., "In vivo imaging of specialized bone marrow endothelial microdomains for tumour engrafment," Nature, vol. 435, no. 7044, pp. 969-973, 2005.
47. S. Méndez-Ferrer, D. Lucas, M. Battista, and P. S. Frenette, "Haematopoietic stem cell release is regulated by circadian oscillations," Nature, vol. 452, no. 7186, pp. 442-447, 2008.
48. S. Méndez-Ferrer, T. V. Michurina, F. Ferraro et al., "Mesenchy-mal and haematopoietic stem cells form a unique bone marrow niche," Nature, vol. 466, no. 7308, pp. 829-834, 2010.
49. C. R. Walkley, G. H. Olsen, S. Dworkin et al., "A microen-vironment-induced myeloproliferative syndrome caused by retinoic acid receptor y defciency," Cell, vol. 129, no. 6, pp. 1097-1110, 2007.
50. C. R. Walkley, J. M. Shea, N. A. Sims, L. E. Purton, and S. H. Orkin, "Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment," Cell, vol. 129, no. 6, pp. 1081-1095, 2007
51. J. Wei, M. Wunderlich, C. Fox et al., "Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia," Cancer Cell, vol. 13, no. 6, pp. 483-495, 2008.
52. D. H. Wiseman, "Donor cell leukemia: a review," Biology of Blood and Marrow Transplantation, vol. 17, no. 6, pp. 771-789, 2011.
53. P. Rameshwar, T. N. Denny, D. Stein, and P. Gascon, "Monocyte adhesion in patients with bone marrow fbrosis is required for the production of fbrogenic cytokines: potential role for interleukin-1 and TGF-jS," Journal of Immunology, vol. 153, no. 6, pp. 2819-2830,1994.
54. M.-C. Martyre, H. Magdelenat, and F. Calvo, "Interferon-y in vivo reverses the increased platelet levels of platelet-derived growth factor and transforming growth factor-jS in patients with myelofbrosis with myeloid metaplasia," British Journal of Haematology, vol. 77, no. 3, pp. 431-435,1991.
55. M.-C. Le Bousse-Kerdilès, S. Chevillard, A. Charpentier et al., "Diferential expression of transforming growth factor-beta, basic fbroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofbrosis and myeloid metaplasia," Blood, vol. 88, no. 12, pp. 4534-4546, 1996.
56. F. Di Raimondo, M. P. Azzaro, G. A. Palumbo et al., "Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofbrosis," Leukemia, vol. 15, no. 6, pp. 976-980, 2001.
57. J. Tiele, H. M. Kvasnicka, and J. Vardiman, "Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl," Best Practice and Research: Clinical Haematology, vol. 19, no. 3, pp. 413-437, 2006.
58. V. Rosti, E. Bonetti, L. Villani et al., "Circulating endothelial solony-forming cells are increased in patients with primary myelofbrosis, do not bear the JAK2-V617F mutation, and coexist with JAK2-V617F positive mature endothelial cells," Haematologica, vol. 94, supplement 2, abstract 0872, pp. 351-0872, 2009.
59. V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms," Blood, vol. 117, no. 9, pp. 2700-2707, 2011.
60. + cells in myelof-brosis with myeloid metaplasia," Blood, vol. 98, no. 12, pp. 3249-3255, 2001.
61. + cells from patients with primary myelofbrosis," STEM CELLS, vol. 26, no. 8, pp. 1920-1930,2008.
62. M. Xu, E. Bruno, J. Chao et al., "Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofbrosis may be due to the action of a number of proteases," Blood, vol. 105, no. 11, pp. 4508-4515, 2005.
63. I. Tabas and C. K. Glass, "Anti-infammatory therapy in chronic disease: challenges and opportunities," Science, vol. 339, no. 6116, pp. 166-172, 2013.
64. H. C. Hasselbalch, "Chronic infammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofbrosis. A human infammation model for cancer development?" Leukemia Research, vol. 37, no. 2, pp. 214-220, 2013.
65. B. Beutler, "Inferences, questions and possibilities in Toll-like receptor signalling," Nature, vol. 430, no. 6996, pp. 257-263, 2004.
66. P. Libby, P. M. Ridker, and G. K. Hansson, "Progress and challenges in translating the biology of atherosclerosis," Nature, vol. 473, no. 7347, pp. 317-325, 2011.
67. A. R. Tall and L. Yvan-Charvet, "Cholesterol, infammation and innate immunity," Nature Reviews Immunology, vol. 15, no. 2, pp. 104-116, 2015.
68. T. Kubota and R. Koike, "Cryopyrin-associated periodic syndromes: background and therapeutics," Modern Rheumatology, vol. 20, no. 3, pp. 213-221, 2010.
69. H. C. Hasselbalch, "The role of cytokines in the initiation and progression of myelofbrosis," Cytokine and Growth Factor Reviews, vol. 24, no. 2, pp. 133-145, 2013.
70. R. Lafyatis, "Transforming growth factor β-at the centre of systemic sclerosis," Nature Reviews Rheumatology, vol. 10, no. 12, pp. 706-719, 2014.
71. M. Shi, J. Zhu, R. Wang et al., "Latent TGF-β structure and activation," Nature, vol. 474, no. 7351, pp. 343-351, 2011.
72. J. Massagué, "TGFβ signalling in context," Nature Reviews Molecular Cell Biology, vol. 13, no. 10, pp. 616-630, 2012.
73. L. Arranz, A. Sánchez-Aguilera, D. Martín-Pérez et al., "Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms," Nature, vol. 512, no. 1, pp. 78-81, 2014.
74. M. Shah, D. M. Foreman, and M. W. J. Ferguson, "Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta," The Lancet, vol. 339, no. 8787, pp. 213-214, 1992.
75. Y. Y. Ho, D. Lagares, A. M. Tager, and M. Kapoor, "Fibrosis-a lethal component of systemic sclerosis," Nature Reviews Rheumatology, vol. 10, no. 7, pp. 390-402, 2014.
76. U. Blank and S. Karlsson, "TGF-beta signaling in the control of hematopoietic stem cells," Blood, vol. 125, no. 23, pp. 3542-3550, 2015.
77. v integrin identifes a core molecular pathway that regulates fbrosis in several organs," Nature Medicine, vol. 19, no. 12, pp. 1617-1624, 2013.
78. N. Benzoubir, C. Lejamtel, S. Battaglia et al., "HCV core-mediated activation of latent TGF-β via thrombospondin drives the crosstalk between hepatocytes and stromal environment," Journal of Hepatology, vol. 59, no. 6, pp. 1160-1168, 2013.
79. F. Ciafoni, E. Cassella, L. Varricchio, M. Massa, G. Barosi, and A. R. Migliaccio, "Activation of non-canonical TGF-beta1 signaling indicates an autoimmune mechanism for bone marrow fbrosis in primary myelofbrosis," Blood Cells, Molecules, and Diseases, vol. 54, no. 3, pp. 234-241, 2015.
80. J. M. Lang, F. Oberling, S. Mayer, and E. Heid, "Auto-immunity in primary myelofbrosis," Biomedicine, vol. 25, no. 1, p. 39, 1976.
81. E. Rondeau, P. Solal-Celigny, D. Dhermy et al., "Immune disorders in agnogenic myeloid metaplasia: relations to myelof-brosis," British Journal of Haematology, vol. 53, no. 3, pp. 467-475, 1983.
82. A. L. Franks and J. E. Slansky, "Multiple associations between a broad spectrum of autoimmune diseases, chronic infammatory diseases and cancer," Anticancer Research, vol. 32, no. 4, pp. 1119-1136, 2012.
83. A. Teferi, R. Vaidya, D. Caramazza, C. Finke, T. Lasho, and A. Pardanani, "Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofbrosis: a comprehensive cytokine profling study," Journal of Clinical Oncology, vol. 29, no. 10, pp. 1356-1363, 2011.
84. J. C. Wang, H. Sindhu, C. Chen et al., "Immune derangements in patients with myelofbrosis: the role of Treg, T17, and sIL2Rα," PLoS ONE, vol. 10, no. 3, Article ID e0116723, 2015.
85. C. Martinaud, C. Desterke, J. Konopacki et al., "Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofbrosis," Genomics Data, vol. 5, pp. 1-2, 2015.
86. M. Krallinger, A. Valencia, and L. Hirschman, "Linking genes to literature: text mining, information extraction, and retrieval applications for biology," Genome Biology, vol. 9, supplement 2, p. S8, 2008.
87. G. Hoermann, S. Cerny-Reiterer, H. Herrmann et al., "Identi-fcation of oncostatin M as a JAK2 V617F-dependent amplifer of cytokine production and bone marrow remodeling in myelo-proliferative neoplasms," The FASEB Journal, vol. 26, no. 2, pp. 894-906, 2012.
88. R. Chaligné, C. Tonetti, R. Besancenot et al., "New mutations of MPL in primitive myelofbrosis: only the MPL W515 mutations promote a G1/S-phase transition," Leukemia, vol. 22, no. 8, pp. 1557-1566, 2008.
89. S. Demyanets, C. Kaun, K. Rychli et al., "Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2-and STAT1/STAT3-dependent pathways and is attenuated by interferon-γ," Basic Research in Cardiology, vol. 106, no. 2, pp. 217-231, 2011.
90. H. Ni, G. Barosi, and R. Hofman, "Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofbrosis," American Journal of Clinical Pathology, vol. 126, no. 2, pp. 241-247, 2006.
91. E. Boveri, F. Passamonti, E. Rumi et al., "Bone marrow microv-essel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations," British Journal of Haematology, vol. 140, no. 2, pp. 162-168, 2008.
92. K. Panteli, M. Bai, E. Hatzimichael, N. Zagorianakou, N. J. Agnantis, and K. Bourantas, "Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases," Hematology, vol. 12, no. 6, pp. 481-486, 2007.
93. D. Rosc, E. Kremplewska-Nalezyta, G. Gadomska, E. Zastawna, A. Michalski, and W. Drewniak, "Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes," Medical Science Monitor, vol. 6, no. 4, pp. 684-691, 2000.
94. M. K. Jensen, R. Riisbro, P. de Nully Brown, N. Brünner, and H. C. Hasselbalch, "Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofbrosis or polycythaemia vera," European Journal of Haematology, vol. 69, no. 1, pp. 43-49, 2002.
95. M. K. Durand, J. S. Bodker, A. Christensen et al., "Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis," Trombosis and Haemostasis, vol. 91, no. 3, pp. 438-449, 2004.
96. P. A. Andreasen, L. Kjøller, L. Christensen, and M. J. Dufy, "The urokinase-type plasminogen activator system in cancer metastasis: a review," International Journal of Cancer, vol. 72, no. 1, pp. 1-22, 1997.
97. P. Leroux, P. L. Omouendze, V. Roy et al., "Age-dependent neonatal intracerebral hemorrhage in plasminogen activator inhibitor 1 knockout mice," Journal of Neuropathology and Experimental Neurology, vol. 73, no. 5, pp. 387-402, 2014.
98. R. P. Czekay, C. E. Wilkins-Port, S. P. Higgins et al., "PAI-1: an integrator of cell signaling and migration," International Journal of Cell Biology, vol. 2011, Article ID 562481, 9 pages, 2011.
99. J. Freytag, C. E. Wilkins-Port, C. E. Higgins et al., "PAI-1 regulates the invasive phenotype in human cutaneous squamous cell carcinoma," Journal of Oncology, vol. 2009, Article ID 963209, 12 pages, 2009.
100. Y. M. Farhat, A. A. Al-Maliki, A. Easa, R. J. O'Keefe, E. M. Schwarz, and H. A. Awad, "TGF-β1 suppresses plasmin and MMP activity in fexor tendon cells via PAI-1: implications for scarless fexor tendon repair," Journal of Cellular Physiology, vol. 230, no. 2, pp. 318-326, 2015.
101. C. Tripodo, S. Sangaletti, C. Guarnotta et al., "Stromal SPARC contributes to the detrimental fbrotic changes associated with myeloproliferation whereas its defciency favors myeloid cell expansion," Blood, vol. 120, no. 17, pp. 3541-3554, 2012.
102. S. Evrard, O. Bluteau, M. Tulliez et al., "Trombospondin-1 is not the major activator of TGF-beta1 in thrombopoietin-induced myelofbrosis," Blood, vol. 117, no. 1, pp. 246-249, 2011.
103. M. Muth, B.M. Engelhardt, N. Kröger et al., "Trombospondin-1 (TSP-1) in primary myelofbrosis (PMF)\-a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia," Annals of Hematology, vol. 90, no. 1, pp. 33-40, 2011.
104. M. Kasprzycka, C. Hammarström, and G. Haraldsen, "Tenascins in fbrotic disorders-from bench to bedside," Cell Adhesion & Migration, vol. 9, no. 1-2, pp. 83-89, 2015.
105. Y. Soini, D. Kamel, M. Apaja-Sarkkinen, I. Virtanen, and V.-P. Lehto, "Tenascin immunoreactivity in normal and pathological bone marrow," Journal of Clinical Pathology, vol. 46, no. 3, pp. 218-221, 1993.
106. M.-C. Martyré, M.-C. Le Bousse-Kerdiles, N. Romquin et al., "Elevated levels of basic fbroblast growth factor in megakary-ocytes and platelets from patients with idiopathic myelofbro-sis," British Journal of Haematology, vol. 97, no. 2, pp. 441-448, 1997.
107. M.-C. Le Bousse-Kerdilès, M.-C. Martyré, and M. Samson, "Cellular and molecular mechanisms underlying bone marrow and liver fbrosis: a review," European Cytokine Network, vol. 19, no. 2, pp. 69-80, 2008.
108. H. Castro-Malaspina and S. C. Jhanwar, "Properties of myelofbrosis-derived fbroblasts," Progress in Clinical and Biological Research, vol. 154, pp. 307-322, 1984.
109. M.-C. Martyré, "TGF-β and megakaryocytes in the pathogen-esis of myelofbrosis in myeloproliferative disorders," Leukemia and Lymphoma, vol. 20, no. 1-2, pp. 39-44, 1995.
110. M. Noda and G. A. Rodan, "Type beta transforming growth factor regulates expression of genes encoding bone matrix proteins," Connect Tissue Research, vol. 21, no. 1-4, pp. 71-75, 1989.
111. Z. C. Han, S. Bellucci, Z. X. Shen et al., "Glycosaminoglycans enhance megakaryocytopoiesis by modifying the activities of hematopoietic growth regulators," Journal of Cellular Physiology, vol. 168, no. 1, pp. 97-104, 1996.
112. S. D. Luikart, C. A. Maniglia, L. T. Furcht, J. B. McCarthy, and T. R. Oegema Jr., "A heparan sulfate-containing fraction of bone marrow stroma induces maturation of HL-60 cells in vitro," Cancer Research, vol. 50, no. 12, pp. 3781-3785, 1990.
113. R. A. Jackson, S. Murali, A. J. Van Wijnen, G. S. Stein, V. Nurcombe, and S. M. Cool, "Heparan sulfate regulates the anabolic activity of MC3T3-E1 preosteoblast cells by induction of Runx2," Journal of Cellular Physiology, vol. 210, no. 1, pp. 38-50, 2007.
114. R. A. Jackson, M. M. McDonald, V. Nurcombe, D. G. Little, and S. M. Cool, "The use of heparan sulfate to augment fracture repair in a rat fracture model," Journal of Orthopaedic Research, vol. 24, no. 4, pp. 636-644, 2006.
115. H. Wu, B. M. Scher, C. L. Chu et al., "Reduction in lactate accumulation correlates with diferentiation-induced terminal cell division of leukemia cells," Diferentiation, vol. 48, no. 1, pp. 51-58, 1991.
116. R. M. Kottmann, A. A. Kulkarni, K. A. Smolnycki et al., "Lactic acid is elevated in idiopathic pulmonary fbrosis and induces myofbroblast diferentiation via pH-dependent activation of transforming growth factor-β," American Journal of Respiratory and Critical Care Medicine, vol. 186, no. 8, pp. 740-751, 2012.
117. L. Boiocchi, C. Vener, F. Savi et al., "Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms," Journal of Clinical Pathology, vol. 64, no. 3, pp. 226-231, 2011.
118. F. Di Raimondo, G. A. Palumbo, S. Molica, and R. Giustolisi, "Angiogenesis in chronic myeloproliferative diseases," Acta Haematologica, vol. 106, no. 4, pp. 177-183, 2001.
119. H. Castro-Malaspina, R. E. Gay, S. C. Jhanwar et al., "Characteristics of bone marrow fbroblast colony-forming cells (CFU-F) and their progeny in patients with myeloproliferative disorders," Blood, vol. 59, no. 5, pp. 1046-1054, 1982.
120. B. R. Greenberg, L. Woo, I. C. Veomett, C. M. Payne, and F. R. Ahmann, "Cytogenetics of bone marrow fbroblastic cells in idiopathic chronic myelofbrosis," British Journal of Haematology, vol. 66, no. 4, pp. 487-490, 1987.
121. J. C. Wang, H.-D. Lang, S. Lichter, M. Weinstein, and P. Benn, "Cytogenetic studies of bone marrow fbroblasts cultured from patients with myelofbrosis and myeloid metaplasia," British Journal of Haematology, vol. 80, no. 2, pp. 184-188, 1992.
122. M. A. Avanzini, M. E. Bernardo, F. Novara et al., "Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms," Leukemia, vol. 28, no. 8, pp. 1742-1745, 2014.
123. R. Campanelli, V. Rosti, L. Villani et al., "Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofbrosis," Cytokine, vol. 53, no. 1, pp. 100-106, 2011.
124. N. Kröger, E. Holler, G. Kobbe et al., "Allogeneic stem cell transplantation afer reduced-intensity conditioning in patients with myelofbrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation," Blood, vol. 114, no. 26, pp. 5264-5270, 2009.
125. J. E. Anderson, G. Sale, F. R. Appelbaum, T. R. Chauncey, and R. Storb, "Allogeneic marrow transplantation for primary myelof-brosis and myelofbrosis secondary to polycythaemia vera or essential thrombocytosis," British Journal of Haematology, vol. 98, no. 4, pp. 1010-1016, 1997.
126. J. Tiele, H. M. Kvasnicka, H. Dietrich et al., "Dynamics of bone marrow changes in patients with chronic idiopathic myelofbrosis following allogeneic stem cell transplantation," Histology and Histopathology, vol. 20, no. 3, pp. 879-889, 2005.
127. H. J. Deeg, T. A. Gooley, M. E. D. Flowers et al., "Allogeneic hematopoietic stem cell transplantation for myelofbrosis," Blood, vol. 102, no. 12, pp. 3912-3918, 2003.
128. F. Cervantes, M. Rovira, A. Urbano-Ispizua, M. Rozman, E. Carreras, and E. Montserrat, "Complete remission of idiopathic myelofbrosis following donor lymphocyte infusion afer failure of allogeneic transplantation: demonstration of a graf-versus-myelofbrosis efect," Bone Marrow Transplantation, vol. 26, no. 6, pp. 697-699, 2000.
129. M. L. Tanner, C. K. Hoh, A. Bashey et al., "FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloab-lative conditioning induces regression of myelofbrosis with myeloid metaplasia," Bone Marrow Transplantation, vol. 32, no. 6, pp. 581-585, 2003.
130. H. Bartsch and J. Nair, "Chronic infammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair," Langenbeck's Archives of Surgery, vol. 391, no. 5, pp. 499-510, 2006.
131. H. C. Hasselbalch, "Perspectives on chronic infammation in essential thrombocythemia, polycythemia vera, and myelof-brosis: is chronic infammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?" Blood, vol. 119, no. 14, pp. 3219-3225, 2012.
132. E. Foran, M. M. Garrity-Park, C. Mureau et al., "Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6," Molecular Cancer Research, vol. 8, no. 4, pp. 471-481, 2010.
133. H. M. O'Hagan, W. Wang, S. Sen et al., "Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands," Cancer Cell, vol. 20, no. 5, pp. 606-619, 2011.
134. C. Augello, U. Gianelli, R. Falcone et al., "PDGFB hypomethy-lation is a favourable prognostic biomarker in primary myelof-brosis," Leukemia Research, vol. 39, no. 2, pp. 236-241, 2015.
135. C. Badouard, M. Masuda, H. Nishino, J. Cadet, A. Favier, and J.-L. Ravanat, "Detection of chlorinated DNA and RNA nucleosides by HPLC coupled to tandem mass spectrometry as potential biomarkers of infammation," Journal of Chromatog-raphy B: Analytical Technologies in the Biomedical and Life Sciences, vol. 827, no. 1, pp. 26-31, 2005.
136. V. Valinluck and L. C. Sowers, "Infammation-mediated cyto-sine damage: a mechanistic link between infammation and the epigenetic alterations in human cancers," Cancer Research, vol. 67, no. 12, pp. 5583-5586, 2007.
137. C. Ospelt, K. A. Reedquist, S. Gay, and P. P. Tak, "Infammatory memories: is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis?" Autoimmunity Reviews, vol. 10, no. 9, pp. 519-524, 2011.
138. M. Jeong, D. Sun, M. Luo et al., "Large conserved domains of low DNA methylation maintained by Dnmt3a," Nature Genetics, vol. 46, no. 1, pp. 17-23, 2014.
139. M. Abu-Remaileh, S. Bender, G. Raddatz et al., "Chronic infammation induces a novel epigenetic program that is conserved in intestinal adenomas and in colorectal cancer," Cancer Research, vol. 75, no. 10, pp. 2120-2130, 2015.
140. Q. Zhang, L. Chen, B. T. Helfand et al., "TGF-β regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence," PLoS ONE, vol. 6, no. 9, Article ID e25168, 2011.
141. Y. Wang, H. Cardenas, F. Fang et al., "Epigenetic targeting of ovarian cancer stem cells," Cancer Research, vol. 74, no. 17, pp. 4922-4936, 2014.
142. G. Sun, M. A. Reddy, H. Yuan, L. Lanting, M. Kato, and R. Natarajan, "Epigenetic histone methylation modulates fbrotic gene expression," Journal of the American Society of Nephrology, vol. 21, no. 12, pp. 2069-2080, 2010.
143. A. J. Kriegel, Y. Fang, Y. Liu et al., "MicroRNA-target pairs in human renal epithelial cells treated with transforming growth factor β1: a novel role of miR-382," Nucleic Acids Research, vol. 38, no. 22, pp. 8338-8347, 2010.
144. A. Teferi, T. L. Lasho, T. Jimma et al., "One thousand patients with primary myelofbrosis: the mayo clinic experience," Mayo Clinic Proceedings, vol. 87, no. 1, pp. 25-33, 2012.
145. F. Olivieri, M. R. Rippo, V. Monsurrò et al., "MicroRNAs linking infamm-aging, cellular senescence and cancer," Ageing Research Reviews, vol. 12, no. 4, pp. 1056-1068, 2013.
146. V617F-mutated cells from the efects of a JAK2 inhibitor," Cancer Research, vol. 71, no. 11, pp. 3831-3840, 2011.
147. J.-J. Kiladjian, C. Chomienne, and P. Fenaux, "Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms," Leukemia, vol. 22, no. 11, pp. 1990-1998, 2008.
148. R. T. Silver, K. Vandris, and J. J. Goldman, "Recombinant interferon-α may retard progression of early primary myelof-brosis: a preliminary report," Blood, vol. 117, no. 24, pp. 6669-6672, 2011.
149. A. M. Vannucchi, P. Guglielmelli, A. Rambaldi, C. Bogani, and T. Barbui, "Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives," Journal of Cellular and Molecular Medicine, vol. 13, no. 8, pp. 1437-1450, 2009.
150. R. Tibes and R. A. Mesa, "Targeting hedgehog signaling in myelofbrosis and other hematologic malignancies," Journal of Hematology and Oncology, vol. 7, article 18, 2014.
151. J. Zou, Y. Hong, Y. Tong et al., "Sonic hedgehog produced by bone marrow-derived mesenchymal stromal cells supports cell survival in myelodysplastic syndrome," Stem Cells International, vol. 2015, Article ID 957502, 13 pages, 2015.